352),/.($0$1$12%$7%('$48,/,1(7(5+$'$3-$1781*
3$'$3(1*2%$7$178%(5.8/26,65(6,67(12%$7
,*XVWL$JXQJ$\X3XWX6UL'DUPD\DQL13XUZDQW\DVWXWL$VFREDW2
1
Program Pendidikan Dokter Spesialis Farmakologi Klinik, FK UI
2
Departemen Farmakologi dan Terapeutik, FK UI
ABSTRACT
Bedaquiline is a new antibiotic particularly developed for the treatment of drug-resistant tuberculosis.
Based on the results of studies during drug development, the safety aspect of bedaquiline to the
heart was a major concern, since it caused prolongation of QT interval. However, this safety
concerns were obtained by observing only small number of patients with incomplete cardiac safety
monitoring data. Additional safety data of the heart needs to be systematically collected after
the drug is widely used as a programmatic drug. Services and patient safety will be enhanced by
implementing active drug safety monitoring (aDSM) from WHO.
Keywords:%HGDTXLOLQHSURORQJDWLRQ47LQWHUYDOVDIHW\SUR¿OH